| High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. | |
| | |
MedLine Citation:
|
PMID: 17368865 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The mainstay of therapy of autoimmune mucocutaneous blistering diseases has been prolonged high-dose systemic corticosteroids and immunosuppressive agents. Recently, high-dose intravenous immunoglobulin (IVIg) has been employed in selected cases, with excellent results in most of them. OBJECTIVE: We sought to evaluate the outcome of the use of IVIg in patients with autoimmune mucocutaneous blistering diseases refractory to conventional therapy or with contraindications for it. METHODS: We performed a retrospective analysis of clinical response to monthly cycles of IVIg in 19 patients affected with autoimmune mucocutaneous blistering diseases: 10 patients with pemphigus vulgaris (PV), 2 with pemphigus foliaceus (PF), 4 with mucous membrane pemphigoid (MMP), 2 with epidermolysis bullosa acquisita, and one with linear IgA bullous dermatosis. RESULTS: Four (21%) of 19 cases presented a complete response (2 PV, 1 MMP and 1 epidermolysis bullosa acquisita). Five (26%) patients did not respond to the treatment (3 PV, 1 PF, 1 MMP). Ten patients (53%) had a partial response. LIMITATIONS: This was a retrospective noncontrolled study with a heterogeneous group of patients. CONCLUSION: The effectiveness of IVIg was inferior to that previously reported. This difference could be attributed to the preparations employed, the different severity of the disease, or individual responses in each patient dependent on Fc receptor gamma polymorphisms. |
| | |
Authors:
|
Sonia Segura; Pilar Iranzo; Isabel Martínez-de Pablo; José Manuel Mascaró; Mercè Alsina; Josep Herrero; Carmen Herrero |
Related Documents
:
|
3606235 - Effects of thymectomy in myasthenia gravis. 786115 - The role of humoral and cellular immune factors in neuromuscular block in myasthenia gr... 22684485 - Failure of reflux inhibitors in clinical trials: bad drugs or wrong patients? 12732085 - Changes in respiratory condition after thymectomy for patients with myasthenia gravis. 23710235 - Differences of excess and deficiency zheng in patients with chronic hepatitis b by urin... 18612925 - Patients with rheumatoid arthritis report greater physical functional deterioration in ... |
Publication Detail:
|
Type: Journal Article Date: 2007-03-21 |
Journal Detail:
|
Title: Journal of the American Academy of Dermatology Volume: 56 ISSN: 1097-6787 ISO Abbreviation: J. Am. Acad. Dermatol. Publication Date: 2007 Jun |
Date Detail:
|
Created Date: 2007-05-16 Completed Date: 2007-06-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7907132 Medline TA: J Am Acad Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 960-7 Citation Subset: IM |
Affiliation:
|
Department of Dermatology, Hospital Clinic, Barcelona, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Autoimmune Diseases / therapy* Epidermolysis Bullosa Acquisita / therapy* Female Humans Immunoglobulins, Intravenous / therapeutic use* Male Middle Aged Pemphigoid, Benign Mucous Membrane / therapy* Pemphigus / therapy* Remission Induction Retrospective Studies Skin Diseases, Vesiculobullous / therapy Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Immunoglobulins, Intravenous |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A reliable surface reconstruction system in biomedicine.
Next Document: Effects of rhamnolipid on degradation of granular organic substrate from kitchen waste by a Pseudomo...